EUGIT Therapeutics

EUGIT Therapeutics – Next generation T cell based cancer immunotherapy

Engineered cancer fighting gamma delta T-cells for off-the-shelf treatment of cancers

We are a therapeutics company that is developing immune cell based therapy for treatment of breast, ovarian and prostate cancers.


Cancer remains an unsolved problem – it is expected that 1.8M new cancer cases and 0.6M cancer deaths will occur this year in the US (source CDC). Although development of immunotherapies such as checkpoint inhibitors and CAR-T cells have shown remarkable clinical success, they work for only a few cancer types. In particular, they do not work for some of the most common types of cancers in women (breast and ovarian) and men (prostate).


Building upon the discoveries of the founders, EUGIT Therapeutics is engineering cancer-fighting immune cells known as the gamma delta T cells which overcome the limitations of existing cancer immunotherapies.

How it works

We take blood from healthy donors and isolate a specific type of immune cell called the gamma delta T cell and then endow them with cancer fighting activity via gene engineering. Our engineered T cells can be used off-the-shelf and ready for infusion into cancer patients.


George Church (Co-Founder and Scientific Advisor): George is a Professor of Genetics at Harvard Medical School and leads Synthetic Biology at the Wyss Institute. His innovations have contributed to nearly all "next generation" DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab's work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics ( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive ).

Nizar Batada (Co-Founder and CEO): Nizar is a cancer biologist with over 20 years of experience working in genomics and cancer research. He did his PhD at Stanford and postdoc with George Church. Previously, he was a tenure track group leader at the University of Edinburgh where he directed a research lab that focused on cancer immunology. Before founding EUGIT therapeutics, he was a senior scientist at 23andMe’s Therapeutics division. The current work he is pursuing at EUGIT therapeutics is based on his discovery of a subtype of tumor infiltrating gamma delta T cells that are associated with good clinical outcomes in breast cancer.